All blog posts
Total 25 results for
Showing 24 out of 25 results
15 August 2023
CAT upholds CMA excessive pricing decision in liothyronine tablets case
15 June 2023
Overview of EU and South African regulatory and competition law in the Pharma sector
09 February 2023
Competition law developments in the pharma sector – 2022 round-up and what to expect in 2023
23 November 2022
SANCTION IMPOSED BY THE SPANISH COMPETITION AUTHORITY ON A PHARMA COMPANY FOR MISUSING LITIGATION STRATEGIES REGARDING PATENTS
11 October 2022
Update on the Teva Copaxone EU case. The EU Commission issues a Statement of Objections against Teva over alleged anti-competitive conduct consisting of misuse of divisional patents and a disparagement campaign against its closest competitor
09 February 2022
Competition law in the pharma sector – Developments and what’s to come in 2022
29 March 2021
CJEU CONFIRMS PAY-FOR-DELAY APPROACH AND UPHOLDS DECISION IN LUNDBECK CASES
04 March 2021
First time EU Commission pursues case relating to divisional patent filing and litigation strategies
16 February 2021
Excessive pricing: EU Commission accepts Aspen’s drug pricing commitments
27 November 2020
The European Commission fines Cephalon and Teva €60.5 million in its fourth “pay-for-delay” decision
27 October 2020
Pharmaceutical sector under increased antitrust scrutiny in the UK
05 June 2020
Advocate General Kokott's Opinion in Lundbeck v Commission
Showing 24 out of 25 results
View moreKey contacts
Kyriakos Fountoukakos
Managing Partner, Competition/Antitrust, Regulation and Trade, Brussels
Veronica Roberts
Partner, Head of Competition/Antitrust, Regulation and Trade, UK, London
Linda Evans
Partner, Head of Competition/Antitrust, Regulation and Trade, Australia, Sydney
Adelaide Luke
Partner, Head of Competition, Asia, Hong Kong
Jean Meijer
Managing Partner, Johannesburg Office, Johannesburg
Kristien Geeurickx
Knowledge Counsel, London